What Is Innoviva, Inc. (INVA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Innoviva, Inc.'s intrinsic value is estimated at $34.06, suggesting a +56.6% average upside from the current price of $21.74. While 7 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: Regime Cross targets $79.82 (+267.2%), versus Dynamic NAV at $9.32 (-57.1%). This +324.3% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About INVA?
12 of 13 models are currently active for INVA. Of these, 7 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates INVA's intrinsic value at $36.03, implying +65.7% upside from the current price. See which stocks rank higher →
How Does INVA Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, INVA ranks #32 by Quality of Company score. CirclFi's QOC score of 8.2/10 evaluates 32 fundamental signals. A score of 8.2 places INVA in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Innoviva, Inc.'s positioning within the Pharmaceutical Preparations segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is INVA a Value Trap?
CirclFi's Value Trap algorithm assigns INVA a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Innoviva, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Innoviva, Inc. earns a quality score of 8.2/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +324.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every INVA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across INVA's 12 active models, average confidence is 48%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad